Luca Santarelli. Therachon
January 7, 2020 05:58 AM ESTUpdated April 23, 08:02 PM
Financing
Startups

Fresh from a Pfiz­er buy­out, Lu­ca Santarel­li’s crew has cre­at­ed a new com­pa­ny — bank­ing new funds and steer­ing their lead drug to a piv­otal

John Carroll

Editor & Founder

Al­most ex­act­ly 3 years since he joined the biotech start­up world as head of Ther­a­chon, the high-pro­file dis­cov­ery sci­en­tist Lu­ca Santarel­li is ready to start …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times